MENLO PARK, Calif., Sept. 11, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will host a conference call on September 12, 2016, at 8:00 a.m. Eastern Time to provide an update on the imetelstat Phase 2 trial in myelofibrosis and Phase 2/3 trial in myelodysplastic syndromes.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID is 80522983. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast will also be available through the company’s website at www.geron.com under Events. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through October 13, 2016.
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.